Short description
TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.
Description
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Last funding
Noway Youcantaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Waltham, Massachusetts, United States, North America
Founded on
January 1, 2018
Exited on
July 15, 2021
Went public on
July 15, 2021
Stock symbol
TCRX
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$56378 - 90123
Sign in for full access
Investors
No Way, Blurry Noaccess, No Way, Uh Ohhhh, Noaccess, No Way, Uh Ohhhh, Noway Youcantaccess, Nopepepe, Noaccess, No Way
Sign in for full access
Founders
Lea Hachigian, Tomasz Kula